野村报告预测,荣昌生物(09995.HK) 去年营收将达78亿元人民币,高于市场预期的52亿元人民币,其中30亿元人民币来自药品销售,按年升25%,48亿元人民币来自合作收入,主要来自艾伯维(ABBV.US) 合作协议的确认收入。该行预测荣昌生物今年毛利率按年升5.4个百分点至94.4%,主要受惠药品毛利率提升及高毛利合作收入占比增加。营运支出将按年升28%至35亿元人民币,扭转去年成本节约趋势...
Source Link野村报告预测,荣昌生物(09995.HK) 去年营收将达78亿元人民币,高于市场预期的52亿元人民币,其中30亿元人民币来自药品销售,按年升25%,48亿元人民币来自合作收入,主要来自艾伯维(ABBV.US) 合作协议的确认收入。该行预测荣昌生物今年毛利率按年升5.4个百分点至94.4%,主要受惠药品毛利率提升及高毛利合作收入占比增加。营运支出将按年升28%至35亿元人民币,扭转去年成本节约趋势...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.